MedPath

Expanded Access for Marizomib

Conditions
Solid Tumor
Registration Number
NCT04644107
Lead Sponsor
Celgene
Brief Summary

This is an expanded access program (EAP) for eligible participants designed to provide access to Marizomib.

Detailed Description

Not available

Recruitment & Eligibility

Status
NO_LONGER_AVAILABLE
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
Exclusion Criteria

Study & Design

Study Type
EXPANDED_ACCESS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Bristol Myers Squibb

🇺🇸

Summit, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath